Repurposing the known anti-hyperglycemic drug Sitagliptin into a stroke medicine: Sitagliptin (brand name: Januvia, Tesavel, Xelevia, and others ), used to bring down high blood glucose levels in Type II diabetes patients, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT, 16/March/2019, 5.46 am

Ribonucleic acid-based therapy for glaucoma:  LncRNA DGCR5 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 16/March/2019, 5.30 am
March 16, 2019
Combinatorial therapy for Deafness: A therapeutic mix encompassing LncRNA HOTAIR, Cholecalciferol, Ajoene and DIM (HCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via upregulation of its target genes, 16/March/2019, 5.58 am
March 16, 2019
Show all

Introduction: What they say 

A recent study from Research Center for Neurobiology and Department of Neurobiology, Xuzhou Medical College, 209 Tongshan Road, Xuzhou, Jiangsu 221004, PR China; and School of Public Health, Xuzhou Medical College, PR China shows that “HO-1 attenuates hippocampal neurons injury via the activation of BDNF-TrkB-PI3K/Akt signaling pathway in stroke. This study was published, in the July 2  2014 issue of the journal Brain Research,  by Prof  Dong, Qi, and others.

Another study from the Department of Pharmacology, Second Military Medical University, Shanghai, China; Department of Science and Education, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China; and Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China (C.-Y.M.) shows that “Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade” This study was published, in the June 9 2015 issue of the journal Stroke,  by Prof  Miao CY, Zhao Y, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Repurposing the known anti-hyperglycemic drug Sitagliptin into a stroke medicine: Sitagliptin (brand name: Januvia, Tesavel, Xelevia, and others ), used to bring down high blood glucose levels in Type II diabetes patients, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT


From research findings to therapeutic opportunity: 

This study suggests, first the first time,

Figure 1. Mechanistic insights into how Valproic acid protects against stroke. Relaxin  protects against stroke via upregulation of its target gene BDNF (Brain-derived growth factor) and NAMPT

Figure 2. Sitagliptin prevents stroke through induction of Brain-derived growth factor (BDNF) and NAMPT.

Sitagliptin, by increasing the expression of its target genes, it may: (1) increase the expression of BDNF and NAMPT (Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide); (2) augment neuronal–BDNF-TrkB-PI3K/Akt–survival pathway; (3) increase sirtuins expression; (4) enhance neural stem cells; (5) promote neural functional recovery; (6) attenuate cerebral /Ischemia-reperfusion injury; (7) inhibit neuronal apoptosis; (8) improve learning and memory.

Together, this study suggests that Sitagliptin may alleviate stroke, and other neurodegenerative diseases (such as multiple sclerosis, cerebral ataxia etc.), promote brain repair and extend the lifespan of an individual. Thus, Sitagliptin or its analogseither alone or in combination with other drugs,” may be used to treat stroke and other neurological deficits. neurological deficits (Figs.1-2).  [easy_payment currency=”USD”]  

 

Details of the idea posted: 

Idea Proposed/Formulated by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $500#

Undisclosed mechanistic information: How does Sitagliptin increase the expression of BDNF and NAMPT?

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References:  

Citation: Boominathan, L., Repurposing the known anti-hyperglycemic drug Sitagliptin into a stroke medicine: Sitagliptin (brand name: Januvia, Tesavel, Xelevia, and others ), used to bring down high blood glucose levels in Type II diabetes patients, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT, 16/March/2019, 5.45 am,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

 

Comments are closed.